Silence Therapeutics plc

Regulatory Filings • Jul 21, 2020

National Storage Mechanism | Additional information

RNS Number : 5527T

Silence Therapeutics PLC

21 July 2020

Silence Therapeutics to Participate in US Virtual Investor Conferences in August

21 July 2020

LONDON, Silence Therapeutics plc (LON: SLN) ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that Company management will be participating in three virtual conferences, details of which can be found below:

William Blair Biotech Focus Conference

Date:		Thursday, August 6, 2020
Time:		2:00 pm EDT (19:00 BST)
Panel:		30 Years of RNA-Targeted Therapies - Where Are We Now

BTIG Virtual Biotechnology Conference

Date:		Monday, August 10, 2020
Time:		9:30 am EDT (14:30 BST)
Webcast link:		Silence Therapeutics fireside chat

Canaccord 40th Annual Growth Conference

Date:		Thursday, August 13, 2020
Time:		11:30 am EDT (16:30 BST)
Webcast link:		Silence Therapeutics presentation

Live webcasts of the BTIG Virtual Biotechnology Conference and the Canaccord Growth Conference can be accessed via the Investors section of the Company's website at www.silence-therapeutics.com. An archived replay of the webcasts will be available for 60 days on the Company's website after the conference.

For more information, please contact:

Silence Therapeutics plc Iain Ross, Executive Chairman Rob Quinn, Chief Financial Officer	Tel:  +44 (0)20 3457 6900
Investec (Nominated Adviser and Broker) Daniel Adams/Gary Clarence	Tel:  +44 (0) 20 7597 5970
European IR Consilium Strategic Communications Mary-Jane Elliott/Chris Welsh/Angela Gray [email protected]	Tel: +44 (0) 20 3709 5700
U.S. IR Westwicke Peter Vozzo [email protected]	Tel: +1 (443) 213-0505

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-associated proteins. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. The Company has secured high value research and collaboration agreements with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

MSCRMMBTMTJTTFM